Our Commitments | Takeda Annual Integrated Report 2026
Our Commitments
Table of Contents
"To continuously and sustainably drive better health for patients through our discovery and delivery of life-transforming medicines, we must uphold the highest standards of ethics and governance, support and develop our people, appropriately manage our environmental impacts and maintain financial discipline. These commitments – summarized in this report – strengthen our resilience and ability to create long‑term value."
Patients
Putting Patients First
At Takeda, every decision begins by putting patients at the center – a principle that has guided and shaped us for 245 years. Our impact is realized through innovative, focused R&D, a resilient global supply network and enabling timely, broad access to our life-transforming treatments and vaccines. Across all of this, we’re scaling data, digital, technology and AI capabilities to unlock speed, quality and efficiency.
In calendar years 2026 and 2027, we expect to launch three transformative medicines and advance the next wave of major programs through key inflection points putting Takeda on a new growth trajectory.
Driving Transformative R&D
We’re embracing emerging science, technologies and partnerships to bring new, highly differentiated therapies to patients faster — fundamentally transforming how we discover, develop and deliver medicines.
In FY2025, we made significant development and regulatory progress, positioning us to translate innovation into commercial performance and setting Takeda on a new growth trajectory.
Investing in Supply and Quality
We are strengthening the efficiency and resilience of our manufacturing and supply networks to serve patients reliably now and into the future.
By combining advanced technology with human expertise, we are transforming our manufacturing and quality ecosystem to be more agile, efficient and resilient for patients. This includes initiatives such as our One Day Batch Release program. It aims to accelerate cycle time, enabling us to release products as quickly as possible after manufacturing.
Accelerating Access
We integrate access into our business strategy and across our operations, from R&D to commercialization. This includes addressing the many complex, structural barriers across countries and within countries that separate patients from the treatments and associated care they need.
In FY2025, we continued to work with health care providers, patient groups, non-governmental organizations and governments worldwide to help address barriers, from improving disease awareness, to screening and diagnosis, treatment and long-term outcomes.
In FY2025, 2,104 new patients were enrolled in Takeda’s affordability-based patient assistance programs.
These programs have helped bridge financial barriers for thousands of patients who would otherwise be unable to access the treatments they need.
People
Supporting Performance and Innovation
Takeda employs approximately 50,000 people around the world. Globally, we invest in developing leadership skills, digital capabilities and an inclusive environment at every level of the business to enable a high-performance culture focused on innovation, efficiency and delivering better outcomes for patients. By scaling data, digital, technology and AI investments, we’re unlocking speed, quality and efficiency across Takeda. This allows us to tap fresh thinking and energy, challenging one another to achieve more together.
Fostering a Culture of Inclusion
Our 11 Takeda Resource Groups bring our culture to life, by fostering an inclusive workplace where all our people feel supported, valued and equipped to grow — enabling them to do their best work. These employee-led communities create inclusive spaces where employees can grow professionally, expand their networks and contribute to innovation and culture at Takeda. In FY2025, one in five of our employees belonged to a Takeda Resource Group.
Planet
Healthier Planet = Healthier People
Recognizing that a healthy environment supports human health, we are working to reduce the environmental impact of our operations and value chain and driving resilience, efficiency and value for our business.
Advancing Our Net-zero Ambition
We are taking decisive action with ambitious science-based targets to reach net-zero emissions across our value chain by FY2040.
To support our Scope 1 and 2 targets, we’ve established comprehensive net-zero roadmaps for our major manufacturing sites to integrate our decarbonization strategy with operational planning. We are enhancing energy efficiency, expanding renewable energy and collaborating to drive innovation that delivers business value while catalyzing progress across the health care ecosystem.
Approximately 90% of our emissions are Scope 3 emissions, meaning they come from outside our own operations – either from the goods and services we use to make our medicines, or from the disposal of our products and packaging after use. To reduce upstream emissions, we are working closely with our suppliers and building sustainability into the design of our products. We are also working to address our hardest-to-abate value chain emissions through cross-sector and industry collaborations and exploring lower-carbon solutions.
Read more about our commitment to the Planet and progress in recent years.
Managing Our Impacts on Nature
Our ability to deliver life-transforming treatments depends on nature, so we work to carefully manage natural resources.
We are making steady progress on our goal to achieve zero waste-to-landfill status at all major locations by FY2030. In FY2025, we also continued to advance responsible water management across our operations through wastewater recovery and reuse systems, enhanced real-time monitoring and upgraded manufacturing equipment.
We also aim to minimize the environmental impact of our products across the entire product life cycle and use life cycle assessments (LCAs) to identify opportunities to do so. In FY2025, we helped to inform an initiative to develop the first international standard for pharmaceutical product life cycle assessments (LCAs), driving progress for the industry.
We are an Early Adopter of the Taskforce on Nature-related Financial Disclosures (TNFD) and published our first TNFD Statement in June 2026.
Value-based Governance
Our obligation to uphold ethical standards goes beyond compliance with laws and regulations. Our values — Integrity, Fairness, Honesty and Perseverance — define who we are and how we act. They provide the foundation for effective governance, maintaining stakeholder trust, and enabling long‑term value creation.
We’re committed to respecting internationally recognized human rights within every aspect of our business, across our value chain, as well as in the communities we serve.
Our Global Code of Conduct sets the foundation for ethical behavior and shared accountability for all employees, outlining our values and expectations in areas such as patient safety, protecting personal data and responsible innovation.
Beyond our own operations, the Takeda Supplier Code of Conduct helps ensure our supplier relationships align with our commitments and our values.